2025-04-05 - Analysis Report
## MicroStrategy Inc. (MSTR) Stock Analysis

**0. Key Figures:**

* **Cumulative Return (MSTR):** 1337.59%
* **Cumulative Return (VOO):** 71.02%
* **Return Difference (MSTR - VOO):** 1266.57%
* **Relative Divergence:** 58.8% (This indicates MSTR's performance is significantly higher than VOO's, relative to its historical performance range.)


**1. Company Overview and Performance Comparison:**

MicroStrategy Inc. is a business intelligence company that provides software and services for enterprise analytics.  MSTR has significantly outperformed the S&P 500 (VOO) over the period considered, showing a cumulative return vastly exceeding that of VOO.  The substantial difference is highlighted by the high relative divergence.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -24.0% | 56.6% | -54.0% | -0.1 | 3.4 |
| 2016-2018  | -20.0% | 27.6% | -37.0% | -0.4 | 3.3 |
| 2017-2019  | -25.0% | 27.6% | -54.0% | -0.1 | 3.7 |
| 2018-2020  | 153.0% | 18.6% | 124.0% | -0.3 | 10.1 |
| 2019-2021  | 173.0% | 36.2% | 98.0% | -0.3 | 14.2 |
| 2020-2022  | 12.0% | 71.4% | -9.0% | -0.0 | 3.7 |
| 2021-2023  | 26.0% | 71.4% | -2.0% | 2.9 | 16.4 |
| 2022-2024  | 1549.0% | 71.4% | 1534.0% | 3.1 | 75.4 |
| 2023-2025  | 1272.0% | 63.9% | 1269.0% | 1.4 | 76.5 |

The table shows high volatility and significant swings in performance, reflected in the large CAGR and MDD values.  Alpha is consistently negative until recently, indicating underperformance relative to the market, except for the last two years where it is significantly positive.  Beta is generally high, implying high sensitivity to market movements.  Market capitalization shows substantial growth over the years.


**2. Recent Price Movement:**

* **Closing Price:** $293.61
* **5-Day Moving Average:** $296.54
* **20-Day Moving Average:** $295.72
* **60-Day Moving Average:** $314.75

The price is slightly below the 5-day and 20-day moving averages, suggesting a minor short-term downtrend.  It's also significantly below the 60-day moving average, indicating a more pronounced medium-term downtrend.  The recent change of +4.01 indicates a positive short-term price movement, potentially a minor recovery.

**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4693 (High Risk)
* **RSI:** 49.83 (Near neutral; neither overbought nor oversold)
* **PPO:** -0.23 (Slightly bearish)
* **Recent Relative Divergence:** 1.2 (Positive, short-term upward trend)
* **Expected Return (2+ years):** 120.5% (significantly higher than the VOO)

The high MRI suggests caution. Although the price has recently increased, other indicators are mixed.  The high expected return relative to the S&P 500 reflects the historical outperformance, however, this is not guaranteed in the future.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|---------------|
| 2024-10-31 | -1.72  | $0.12 B       |
| 2024-08-06 | -5.74  | $0.11 B       |
| 2024-05-01 | -3.09  | $0.12 B       |
| 2023-11-01 | -10.09 | $0.13 B       |
| 2024-10-31 | -1.01  | $0.13 B       |


The company is currently reporting negative EPS, suggesting losses.  Revenue is relatively stable but low.  This is a concerning trend that needs further investigation. There's also a duplicate entry for October 31, 2024. Data inconsistencies need clarification.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.12B | 71.69% |
| 2024-09-30 | $0.12B | 70.41% |
| 2024-06-30 | $0.11B | 72.24% |
| 2024-03-31 | $0.12B | 73.96% |
| 2023-12-31 | $0.12B | 77.33% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $18.23B | -3.68% |
| 2024-09-30 | $3.77B | -9.01% |
| 2024-06-30 | $2.83B | -3.62% |
| 2024-03-31 | $2.40B | -2.21% |
| 2023-12-31 | $2.16B | 4.12% |

Despite relatively high profit margins, the negative ROE and fluctuating equity figures raise serious concerns about the company's financial health and sustainability.  The significant jump in Equity in Q4 2024 requires further investigation.


**6. Overall Analysis:**

MicroStrategy's past performance has been exceptionally strong, significantly outperforming the S&P 500. However, recent financial statements reveal substantial losses and inconsistent data, raising major red flags.  While the long-term expected return is high, the high risk indicated by the MRI and the negative ROE  suggest a significant level of risk.  Further investigation into the inconsistencies in the provided data and a deeper dive into the company's recent business strategy and future prospects are crucial before making any investment decisions.  The current positive short-term price movement might be a temporary bounce, and investors should exercise caution.
